AKT1 and psoriasis vulgaris: Thus far, efforts to inhibit mTOR-associated pathways (e.g., rapamycin) have achieved only limited efficacy for treatment of plaque psoriasis [86, 87], although some efficacious topical agents are known to inhibit AKT/mTOR signaling [88, 89].